Trial Profile

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Domatinostat (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms EMERGE

02 Jul 2022 Results (n=21) reporting safety and efficacy data from oesophagogastric and colorectal adenocarcinoma cohorts presented at the 24th World Congress on Gastrointestinal Cancer
01 Feb 2022 Status changed from recruiting to discontinued, according to a 4SC media release.
01 Feb 2022 According to a 4SC AG media release, the company has decided to discontinue development of domatinostat because clinical information now available, and which will be published in due course, indicates that domatinostat is unlikely to provide value to patients, physicians, or shareholders.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com